Clinical Trial Update: Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Primary or Metastatic Brain Cancers [Phase 1, Phase 2]

View source ↗

Summary

A radiolabeled monoclonal antibody therapy was studied in a Phase 1/2 trial for primary and metastatic brain cancers; the study status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Brain Tumor
• Cancer

Snippet

Sponsor: Duke University | Conditions: Brain and Central Nervous System Tumors, Metastatic Cancer | Phase 1, Phase 2 | Status: COMPLETED